Angiotensinogen (AGT) Antibody (FITC)

Este producto es parte de AGT - Angiotensinogen
Product Graph
442€ (200 µl)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Angiotensinogen (AGT) Antibody (FITC)
category
Primary Antibodies
provider
Abbexa
reference
abx274115
tested applications
WB, IHC, IF/ICC

Description

Angiotensinogen (AGT) Antibody (FITC) is a Rabbit Polyclonal antibody conjugated to FITC against Angiotensinogen (AGT).

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Angiotensinogen (AGT)
Host
Rabbit
Reactivity
Rat
Recommended Dilution
WB: 0.5-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
FITC
Isotype
IgG
Purification
Purified by antigen-specific affinity chromatography.
Size 1
200 µl
Size 2
1 ml
Form
Liquid
Tested Applications
WB, IHC, IF/ICC
Buffer
0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol.
Availability
Shipped within 5-15 working days.
Storage
Aliquot and store at -20°C. Avoid exposure to light. Avoid repeated freeze/thaw cycles.
Dry Ice
No
Alias
ANHU,SERPINA8,hFLT1
Background
Antibody anti-AGT
Status
RUO

Descripción

Angiotensinogen (AGT) is a protein primarily produced and secreted by the liver, although it is also synthesized by other tissues, including the kidney and adipose tissue. It serves as the precursor molecule for the renin-angiotensin system (RAS), a key regulatory pathway involved in blood pressure regulation, fluid balance, and electrolyte homeostasis. AGT is converted into angiotensin I by the enzyme renin, which is released by the kidneys in response to various stimuli, such as decreased blood pressure or sodium levels. Angiotensin I is further converted into angiotensin II by angiotensin-converting enzyme (ACE), leading to vasoconstriction, aldosterone release, and sodium reabsorption, ultimately raising blood pressure. Dysregulation of the RAS, including alterations in AGT levels, has been implicated in hypertension, cardiovascular disease, and kidney disorders. Therapeutic interventions targeting the RAS, such as ACE inhibitors and angiotensin receptor blockers, are commonly used to manage hypertension and related conditions. Understanding the role of AGT in the RAS provides insights into cardiovascular health and potential avenues for therapeutic intervention. Ongoing research continues to elucidate the intricate mechanisms underlying AGT regulation and its implications for human health and disease

Related Products

EH0550

Human AGT(Angiotensinogen) ELISA Kit

Ver Producto
EM0458

Mouse Agt(Angiotensinogen) ELISA Kit

Ver Producto
EP0340

Porcine AGT(Angiotensinogen ) ELISA Kit

Ver Producto